Considering that clinical trials with Flt3L and CD40 agonist have been tested for multiple solid tumors, this research provides experimental evidence and clinical basis for DC-targeted immune therapy against pancreatic cancer treatments. This evidence concerns the gene FLT3LG and pancreatic neoplasm.